Several pharmacological therapies targeting the IL-6 signaling pathway, mainly by using anti-IL-6 or anti-IL-6R antibodies or blockers, have had preventive effects in cancer-evoked cachexia (150, 151), restored muscle function in a mouse model of muscular dystrophy (152), and ameliorated muscle atrophy induced by tail suspension in mice (153). Here, IL6 is linked to muscular dystrophy.